The contrOL of dYslipideMia in outPatIent clinics in GreeCe (OLYMPIC) study

Angiology

Volumn 56, Issue 6, 2005, Pages 731-741

  Diamantopoulos, E J ^a   Athyros, V G ^a   Yfanti, G K ^a   Migdalis, E N ^a   Elisaf, M ^a   Vardas, P E ^a   Manolis, A S ^a   Karamitsos, D T ^a   Ganotakis, E S ^a   Hatseras, D ^a  

^a NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; THYROID HORMONE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GREECE; HEALTH PROMOTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; SMOKING;

EID: 29044433488     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600611     Document Type: Article

References (35)

1. Scandinavian Simvastatin Survival Study (4S) Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383-1389, 1994.
2. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996.
3. Long-term Intervention with Pravastatin Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998.
4. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized, placebo-controlled trial. Lancet 360:7-22, 2002.
5. Athyros VG, Papageorgiou AA, Mercouris BR, et al: Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary Coronary Heart Disease prevention: The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220-228, 2002.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24:1601-1610, 2003.
8. Pearson TA, Laurora I, Chu H, et al: The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160:459-467, 2000.
9. Ruof J, Klein G, Marz W, et al: Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: The gap between treatment guidelines and real life treatment patterns. Prev Med 35:48-53, 2002.
10. Durrington P: The human and economic costs of undertreatment with statins. Int J Clin Pract 56:357-368, 2002.
11. Fonarow GC, French WJ, Parsons LS, et al: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3. Circulation 103:38-44, 2001.
12. Brown AS: Cofer LA. Lipid management in a private cardiology practice (the Midwest Heart experience). Am J Cardiol 85:18A-22A, 2000.
13. Kinn JW, Brown AS: Cardiovascular risk management in clinical practice: The Midwest Heart Specialists experience. Am J Cardiol 89:23C-29C, 2002.
14. Vale MJ, Jelinek MV, Best JD, and the COACH study group: Coaching patients on achieving cardiovascular health. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 176:211-215, 2002.
15. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, et al: Undertreatment of hypercholesterolaemia: A population-based study. Br J Clin Pharmacol 55:389-397, 2003.
16. Pearson TA: The undertreatment of LDL-cholesterol: Addressing the challenge. Int J Cardiol 74(suppl 1)S23-S28, 2000.
17. Hoerger TJ, Bala MV, Bray JW, et al: Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 82:61-65, 1998.
18. National Cholesterol Education Program, Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89:1333-1445, 1994.
19. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al, for the MetS-GREECE Collaborative Group: The prevalence of the METabolic Syndrome in GREECE-The MetS-GREECE Multicenter Study. Diabetes Obesity Metab 2004 (in press).
20. Athyros VG, Elisaf M, Mikhailidis DP: Undertreatment of dyslipidaemia in Greece. Atherosclerosis 177:215-216, 2004.
21. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al, for the METS-Greece Collaborative Group: Prevalence of atherosclerotic cardiovascular disease among subjects with the metabolic syndrome with or without diabetes mellitus. Curr Med Res Opin 20:1691-1701, 2004.
22. Grundy SM, Cleeman JI, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004.
23. Cannon CP, Braunwald E, McCabe CH, et al: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:495-504, 2004.
24. Sever PS, Dahlof B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre, randomised, controlled trial. Lancet 361:1149-1158, 2003.
25. Andrews TC, Ballantyne CM, Hsia JA, et al: Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med 111:185-191, 2001.
26. Bowker TJ, Clayton TC, Ingham JE, et al: A British Cardiac Society survey of the potential for secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 75:334-342, 1996.
27. The EUROASPIRE Study Group: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 18:1569-1582, 1997.
28. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22:554-572, 2001.
29. Alzahrani T, Marrat S, Haider A: Management of dyslipidemia in primary care. Can J Cardiol 19:1499-1502, 2003.
30. Tuomilehto J, Rastenyte D, Jousilahti P, et al: Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 27:210-215, 1996.
31. Hu FB, Stampfer MJ, Solomon CG, et al: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 161:1717-1723, 2001.
32. Almdal T, Scharling H, Jensen JS, et al: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 164:1422-1426, 2004.
33. Athyros VG, Papageorgiou AA, Symeonidis AN, et al: Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Angiology 54:679-690, 2003.
34. Colhoun HM, Betteridge DJ, Durrington PN, et al, for the CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre, randomised, placebo-controlled trial Collaborative AtoRvastatin Diabetes Study (CARDS). Lancet 364:685-696, 2004.
35. American Heart Association: 2003 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2002.